PMHNP Scope of Practice for Anxiety in Illinois

If you’re a psychiatrist or PMHNP treating anxiety disorders, you’re navigating one of the most complex regulatory landscapes in modern medicine. Between federal DEA rules, state-specific prescribing laws, and ever-changing telehealth regulations, staying compliant while delivering quality care can feel like walking a tightrope.

Here’s the reality: the rules for prescribing anxiety medications via telehealth vary dramatically by state and provider type. A PMHNP in Texas faces entirely different constraints than one in New York. A psychiatrist treating panic disorder in Florida must follow different controlled substance rules than one in California. And all of this sits on top of federal DEA regulations that have been in temporary extension mode since 2020.

This guide cuts through the complexity. We’ll walk through what you actually need to know about prescribing anxiety medications via telehealth — the federal baseline, how state laws differ, what it means for psychiatrists versus PMHNPs, and how to stay compliant while building a thriving anxiety-focused practice.

The Federal Baseline: DEA Rules on Telehealth Prescribing

Let’s start with the foundation that applies nationwide: federal DEA regulations.

Under normal circumstances, the Ryan Haight Act prohibits prescribing controlled substances ‘by means of the Internet’ without a prior in-person medical evaluation. That law was designed to prevent rogue online pharmacies from flooding the market with opioids and other controlled drugs.

For anxiety treatment, this matters because many effective medications — particularly benzodiazepines like alprazolam (Xanax), lorazepam (Ativan), and clonazepam (Klonopin) — are Schedule IV controlled substances. Under pre-COVID rules, you couldn’t start a patient on Xanax via telehealth alone; you’d need to see them in person first.

But here’s where things changed dramatically.

When COVID-19 hit in March 2020, the DEA invoked public health emergency exceptions that allowed controlled substance prescribing via telehealth without any in-person exam. Initially temporary, these flexibilities have been extended repeatedly. Most recently, in November 2024, the DEA announced a third extension through December 31, 2025.

What this means for your practice right now: As of February 2026, you can legally initiate benzodiazepine therapy for a new anxiety patient via telehealth — a video evaluation alone satisfies federal requirements. You don’t need an in-person visit first, as long as you’re conducting a legitimate evaluation via real-time audio-visual technology and following state laws.

This has been transformative for anxiety care. Patients with agoraphobia who can’t leave their homes, rural patients hours from the nearest psychiatrist, working professionals who can’t take time off — all can now access evidence-based pharmacotherapy without the in-person barrier.

The catch? This flexibility is temporary.

The DEA proposed permanent rules in 2023 that would have reinstated the in-person requirement (allowing only a 30-day telehealth prescription before mandating an office visit). After receiving over 38,000 public comments — many from mental health providers and patients arguing this would devastate access to care — the DEA pulled back to reconsider. They’re working on ‘a new path forward for telemedicine,’ but no one knows exactly what that will look like or when it will arrive.

What you should do: Continue prescribing anxiety medications via telehealth under the current extension, but prepare for potential changes. Consider developing relationships with local clinics for in-person evaluations if needed, or be ready to transition to a hybrid model. Platforms like Klarity Health are watching these developments closely and will adapt their infrastructure to keep providers compliant when rules change.

For non-controlled anxiety medications (SSRIs, SNRIs, buspirone, hydroxyzine), none of this matters — you can prescribe them via telehealth with no restrictions beyond standard of care.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrists: Full Authority, But State-Specific Requirements

If you’re a psychiatrist (MD or DO), your scope of practice for anxiety treatment is straightforward: you have full independent authority to evaluate, diagnose, and prescribe in every state. No supervision required, no formulary restrictions, no collaborative agreements.

You can prescribe any medication from SSRIs to benzodiazepines to beta-blockers, conduct psychotherapy if you choose, and make all treatment decisions independently. This autonomy is one reason platforms recruiting providers for telehealth value psychiatrists highly — there are no scope-of-practice landmines to navigate.

But autonomy doesn’t mean freedom from regulation. Here’s what you must navigate:

Multi-State Licensure

You need a valid medical license in every state where your patients are located. Treating a patient in Texas while you’re only licensed in California is illegal — full stop.

Some states make this easier through the Interstate Medical Licensure Compact (IMLC). Texas, Illinois, Pennsylvania, and Florida are IMLC members, which streamlines getting licenses if you’re already licensed in another IMLC state. California and New York are not in the compact, so you must go through their individual licensing processes.

For a busy telehealth practice, managing multiple state licenses is non-negotiable. If you’re joining a platform like Klarity, they typically assist with the licensing process since they need providers credentialed in high-demand states.

Prescription Drug Monitoring Programs (PDMPs)

Every state now requires checking the state PDMP before prescribing controlled substances. For anxiety treatment with benzodiazepines, this means:

• New York: You must check the I-STOP registry before every Schedule II–IV prescription. Not just the first one — every single time you prescribe or refill Xanax, Klonopin, etc.

• Florida: Check E-FORCSE before any controlled substance prescription and at least every 3 months for ongoing therapy.

• Pennsylvania: Must check before initial benzodiazepine or opioid prescriptions and for each subsequent prescription (not just refills — each time).

• Texas: Mandatory check before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol.

• California: Check CURES at least every 4 months when continuing controlled substance therapy.

• Illinois: Required for Schedule II prescriptions; strongly encouraged (and functionally expected) for all controlled substances.

Most EHR systems now integrate PDMP queries, making this quick. But it’s a hard requirement — state medical boards do audit compliance, and failure to check can result in disciplinary action.

Electronic Prescribing Requirements

Most states now mandate e-prescribing for controlled substances:

• California and New York require e-prescribing for all medications, controlled or not.
• Florida, Pennsylvania, and Illinois require it for controlled substances specifically.
• Texas strongly encourages it and Medicare requires it.

You’ll need DEA-compliant e-prescribing software with two-factor authentication (EPCS – Electronic Prescribing of Controlled Substances). Telehealth platforms typically provide this integrated into their systems.

Documentation and Standard of Care

Even via telehealth, you must conduct an evaluation equivalent to in-person standards. For anxiety disorders, this means:

• Detailed psychiatric history
• Mental status examination (observing the patient on video, asking questions, noting appearance, affect, thought process)
• Assessment of symptom severity and functional impairment
• Ruling out medical causes or substance-induced anxiety
• Discussion of treatment options and informed consent

Document that the visit was conducted via telehealth and meets standard-of-care requirements. Some states (like Florida) explicitly require documenting patient consent for telehealth treatment.

State-Specific Prescribing Rules

While psychiatrists can prescribe controlled substances in all states, some have specific conditions:

• Texas prohibits any provider from prescribing Schedule II controlled substances for chronic pain via telemedicine (with narrow exceptions). This doesn’t affect anxiety treatment — it’s targeting opioid prescribing — but it illustrates Texas’s regulatory approach.

• Florida bans Schedule II prescribing via telehealth except for psychiatric treatment, inpatient care, hospice, or nursing homes. The psychiatric exception means you can prescribe stimulants for comorbid ADHD/anxiety via telehealth, but the same medication for weight loss would be prohibited.

Bottom line for psychiatrists: Your clinical scope is unlimited, but administrative compliance requires attention to state-specific prescribing laws, PDMP requirements, and licensing. Once you’re properly set up, the practice model is clean — you can independently treat anxiety patients across multiple states via telehealth with appropriate medications.

PMHNPs: Powerful Providers, Variable Regulations

Psychiatric Mental Health Nurse Practitioners are critical to meeting the demand for anxiety treatment — there simply aren’t enough psychiatrists. PMHNPs diagnose and treat anxiety disorders in all 50 states, but the regulatory landscape varies dramatically based on where you practice.

The two big variables: practice authority (can you work independently or do you need physician collaboration?) and controlled substance prescribing limits.

Practice Authority by State

Full Practice Authority (FPA) States:

• Illinois: PMHNPs with 4,000+ hours of clinical experience can apply for Full Practice Authority. Once granted, you practice independently — no physician oversight required for most prescribing (with a specific nuance on Schedule II opioids in your first 5 years of FPA).

• New York: After 3,600 hours of practice, you can practice without a collaborative agreement. This became permanent law in 2022. Before hitting that threshold, you need a physician collaborator on file.

• California: In transition. As of 2023, experienced NPs can practice independently in certain settings (group practices, clinics). By January 2026, qualified NPs can apply for full independence in all settings. Until then, you operate under standardized procedures with a physician.

Restricted Practice States:

• Texas: You must have a Prescriptive Authority Agreement (PAA) with a physician. That physician can supervise up to 7 NPs/PAs and must approve your prescribing scope.

• Florida: PMHNPs need a supervising physician with a written protocol. (Florida’s 2020 independent practice law excluded psychiatric NPs — it only applied to primary care specialties.)

• Pennsylvania: Requires a collaborative agreement with a physician. The physician doesn’t have to be on-site but is officially responsible for oversight.

For telehealth platforms, this creates operational complexity. In Texas, Florida, and Pennsylvania, the platform must provide physician collaborators for PMHNPs to prescribe legally. In New York and Illinois (for experienced NPs), no collaborator is needed, making deployment simpler.

Controlled Substance Prescribing: The Real Constraint

This is where state variation gets significant. Every PMHNP must obtain DEA registration and typically a state controlled substance license. But then states impose different limits:

Schedule II Restrictions:

Schedule II includes stimulants (relevant for comorbid ADHD/anxiety) and certain barbiturates. Many states restrict or prohibit NP prescribing of Schedule II:

• Texas: APRNs cannot prescribe Schedule II in outpatient settings except in hospitals or hospice care. Period. If a Texas PMHNP has a patient with comorbid ADHD who needs Adderall, the collaborating physician must prescribe it.

• Florida: NPs cannot prescribe Schedule II for more than 7 days unless they’re a certified psychiatric nurse treating mental illness. This exception means Florida PMHNPs can prescribe stimulants for ADHD without the 7-day limit, but general NPs cannot.

• Pennsylvania: Allows Schedule II prescribing up to 30-day supply if included in the collaborative agreement and the physician is notified within 24 hours.

• Illinois, New York, California: Generally allow NP prescribing of Schedule II with appropriate authority (whether through collaboration or independence).

Schedule IV (Benzodiazepines):

This is the most relevant class for anxiety treatment. Good news: virtually all states allow PMHNPs to prescribe benzodiazepines with appropriate authority.

• Pennsylvania: Up to 90-day supply per prescription, must be in your collaborative agreement.

• Florida: No specific quantity limit beyond general controlled substance laws; protocol must include this authority.

• Texas, Illinois, New York, California: Allowed per your scope (collaboration agreement in restrictive states, independent in FPA states).

The practical reality: If you’re treating garden-variety anxiety disorders (GAD, panic disorder, social anxiety), you can prescribe SSRIs, SNRIs, benzodiazepines, and other medications in any state. Where it gets complicated is if you’re also treating ADHD (common comorbidity) or using certain sedatives — then Schedule II restrictions may require physician involvement in some states.

PDMP and Documentation Requirements

PMHNPs follow the same PDMP check requirements as physicians in each state. In New York, you check I-STOP every time. In Pennsylvania, every time for benzos. In California, every 4 months for continuing therapy.

Documentation standards are identical too: thorough evaluation, informed consent, treatment plan, standard of care. Some states explicitly require documenting that you’re practicing within your scope of authority and following your collaborative agreement (if you have one).

The Trend: More Autonomy

From 2016 to 2025, the trend has been clear: more states are granting full practice authority to experienced NPs. Over half of states now have FPA. The driver is provider shortage — particularly acute in psychiatry and especially in rural areas.

But the largest states by population (California, Texas, Florida, Pennsylvania) still have restrictions, meaning a huge portion of potential patients live in places where PMHNPs need physician collaborators. For platforms like Klarity, this means maintaining a network of collaborating psychiatrists in restricted states to enable PMHNP prescribers.

State-by-State Breakdown: What Actually Matters

Let’s cut to the practical details for the six highest-demand states:

California

For Psychiatrists:

• Must have California medical license (not in IMLC — apply directly)
• No in-person exam required by state law if telehealth evaluation meets standard of care
• Check CURES PDMP every 4 months for controlled substance therapy
• E-prescribe everything (mandatory for all prescriptions since 2022)
• No state-specific telehealth prescribing restrictions beyond federal law

For PMHNPs:

• Transitioning to full practice — by 2026, experienced NPs can practice fully independently
• Until then, work under standardized procedures with physician approval
• Can prescribe controlled substances (including benzodiazepines) with furnishing authority and DEA registration
• Same PDMP and e-prescribing requirements as MDs

Texas

For Psychiatrists:

• Texas license required (IMLC member — easier path if licensed in another IMLC state)
• Must establish care via real-time audio-visual exam (video)
• Can prescribe anxiety meds via telehealth; cannot use telehealth for Schedule II chronic pain prescriptions (doesn’t affect mental health)
• Mandatory PDMP check for opioids, benzos, barbiturates, carisoprodol

For PMHNPs:

• Must have Prescriptive Authority Agreement with physician
• Cannot prescribe Schedule II in outpatient settings (hospital/hospice only) — major limitation if treating ADHD
• Can prescribe benzodiazepines for anxiety per PAA scope
• Video exam required for new patients

Florida

For Psychiatrists:

• Florida license required OR special out-of-state telehealth provider registration (relatively unique option)
• Schedule II via telehealth allowed for psychiatric treatment (exception to general ban)
• Must obtain patient consent for telehealth (document it)
• Check E-FORCSE PDMP before any controlled prescription and every 90 days
• E-prescribe all controlled substances

For PMHNPs:

• Need physician supervision protocol (not included in FL’s primary care NP independence)
• Schedule II limited to 7 days unless you’re a certified psychiatric nurse treating mental illness (then no limit)
• Can prescribe benzodiazepines per protocol
• Same PDMP and consent requirements

New York

For Psychiatrists:

• NY license required (not in IMLC — direct application)
• No state restriction on telehealth prescribing; standard of care evaluation required
• Must check I-STOP PMP before every Schedule II–IV prescription (not just first — every time)
• E-prescribe everything (mandatory since 2016)

For PMHNPs:

• Full practice authority after 3,600 hours (permanent as of 2022)
• Before that threshold: need collaborative agreement
• Can prescribe all schedules independently after FPA (no NP-specific controlled substance limits)
• Same PDMP (every prescription) and e-prescribing requirements

Pennsylvania

For Psychiatrists:

• PA license (IMLC member since 2017)
• No statutory telehealth prescribing restrictions; standard of care applies
• Must check PA PDMP before initial benzo or opioid prescription and for each subsequent prescription
• E-prescribe controlled substances (mandatory since 2019)

For PMHNPs:

• Must have collaborative agreement with physician
• Schedule II: up to 30-day supply (physician notified within 24 hours)
• Schedule IV benzos: up to 90-day supply
• Prescribing scope must be detailed in collaborative agreement
• Same PDMP requirements (every benzo prescription)

Illinois

For Psychiatrists:

• IL license (IMLC member since 2018)
• Telehealth permitted including audio-only for mental health when necessary
• Check IL PMP for Schedule II; expected for all controlled substances
• Need state controlled substance license plus DEA registration
• E-prescribe controls

For PMHNPs:

• Full Practice Authority available after 4,000 hours + training
• FPA NPs prescribe independently except consultation relationship required for Schedule II opioids (first 5 years)
• Can prescribe benzodiazepines independently under FPA
• Without FPA: collaborative agreement required (physician can oversee up to 5 NPs)
• Same PDMP and state CS license requirements

The Economics: Why This All Matters for Your Practice

Understanding these regulations isn’t just about compliance — it’s about economics and patient flow.

The Traditional Marketing Math Doesn’t Work:

If you’re trying to build an anxiety-focused practice solo, patient acquisition is expensive. Real numbers:

• Google Ads for ‘anxiety psychiatrist’ or ‘panic attack treatment’ run $15-40+ per click
• Most clicks don’t convert to booked patients
• Realistic cost per booked patient through PPC: $200-400+ once you factor in ad spend, click waste, and no-shows
• SEO takes 6-12 months of consistent investment before generating meaningful patient flow
• Directory listings (Psychology Today, Zocdoc) charge monthly fees AND per-booking fees — and you’re competing with hundreds of providers on the same page
• When you add up agency fees, failed campaigns, staff time qualifying leads — DIY marketing typically costs $3,000-5,000/month with uncertain results

The Platform Economics:

This is where understanding multi-state regulations becomes valuable. Platforms like Klarity Health handle:

• Patient acquisition at scale (pre-qualified patients matched to your specialty and availability)
• Multi-state licensing support (helping you get credentialed in high-demand states)
• Compliance infrastructure (collaborating physicians for NPs in restricted states, PDMP integration, e-prescribing systems)
• Telehealth technology (no separate platform costs)
• Both insurance and cash-pay patient flow

You pay a standard listing fee per new patient lead — only when you see patients. No upfront marketing spend, no monthly subscription fees, no wasted ad dollars.

Why multi-state matters: A psychiatrist or experienced PMHNP who can treat patients in 5-6 states has significantly more patient availability than someone limited to one state. If you’re licensed in California, Texas, Florida, New York, Pennsylvania, and Illinois — congratulations, you can access roughly 45% of the U.S. population. More patient availability = fuller schedule = better income stability.

The regulatory knowledge helps you prioritize: If you’re a PMHNP, getting licensed in New York or Illinois (FPA states) might be more valuable than Florida or Texas (restricted) because you can operate independently. If you’re a psychiatrist, Florida’s out-of-state telehealth registration is a much faster path than California’s full licensing process.

Preparing for Regulatory Changes

The DEA’s telehealth extension runs through December 31, 2025. What happens after that is uncertain. Here’s how to prepare:

Best Case: DEA makes current flexibilities permanent (allowing telehealth-only prescribing of controlled substances). Continue as you are.

Likely Case: DEA introduces a hybrid requirement — perhaps allowing initial prescribing via telehealth but requiring an in-person exam within 30-180 days for ongoing therapy. This would require developing relationships with local clinics or exam providers in states where you practice.

Worst Case: Full reinstatement of in-person requirement before prescribing controlled substances. This would significantly disrupt telehealth anxiety treatment (especially benzodiazepine therapy).

What you can do now:

1. Stay informed: Subscribe to DEA updates, follow industry groups (American Psychiatric Association, American Telemedicine Association)

2. Document thoroughly: Make sure your telehealth evaluations are comprehensive and clearly documented — if your records show you’re conducting thorough, appropriate exams, you’re protected

3. Develop hybrid models: Consider establishing relationships with exam providers or clinics in your key states

4. Communicate with patients: When prescribing controlled substances via telehealth, let patients know this is under temporary federal rules and may require an in-person visit in the future

5. Choose partners carefully: If joining a telehealth platform, ask how they’re preparing for regulatory changes — platforms with infrastructure to adapt quickly will keep you practicing legally

FAQ: Telehealth Prescribing for Anxiety Treatment

Can I prescribe benzodiazepines to a new patient via telehealth in 2026?

Yes, under current federal DEA rules (extended through December 31, 2025 and likely beyond). You must conduct a real-time audio-visual evaluation meeting standard of care, comply with state laws (PDMP checks, e-prescribing, licensure), and document appropriately. First-line anxiety medications (SSRIs, SNRIs) have no restrictions.

Do I need an in-person exam before prescribing anxiety medications via telehealth?

For non-controlled medications (SSRIs, buspirone, hydroxyzine): No state requires an in-person exam if your telehealth evaluation meets standard of care. For controlled substances (benzodiazepines): Currently no, under federal waivers. After December 31, 2025, this may change depending on final DEA rules.

Can a PMHNP prescribe Xanax independently?

Depends on the state. In full-practice states (NY after 3,600 hours, IL with FPA, CA moving toward it), yes. In restricted states (TX, FL, PA), you need a physician collaborative agreement that includes benzodiazepine prescribing authority. The medication itself (Schedule IV) is generally allowed for NPs nationwide, but the collaboration requirement varies.

What’s the difference between psychiatrist and PMHNP prescribing authority for anxiety?

Psychiatrists have full independent prescribing authority in all states — no supervision or collaboration required. PMHNPs can prescribe the same medications (including benzodiazepines for anxiety) but may need physician oversight depending on the state. For typical anxiety treatment (SSRIs, SNRIs, benzos), both can manage care effectively. The constraint is administrative (collaboration requirements) not clinical.

Do I have to check the PDMP every time I refill a benzodiazepine?

Depends on state law. New York: yes, every time. Pennsylvania: yes, every time for benzos. Florida: at least every 90 days. California: at least every 4 months. Texas: before initial prescription and periodically (best practice is each time). Illinois: for Schedule II definitely; best practice for all controlled substances. Check your specific state requirements.

Can I treat patients via telehealth if they’re in a different state than me?

Only if you’re licensed in the state where the patient is physically located during the visit. The patient’s location determines which state’s laws apply — your location is irrelevant. You need licensure in every state where you have patients. Interstate compacts (IMLC for physicians, NLC for nurses) can streamline this but don’t eliminate the requirement.

What happens if DEA eliminates telehealth prescribing flexibility?

If DEA reinstates the in-person exam requirement for controlled substances, you’d need to see benzodiazepine patients in person before prescribing or arrange for them to have an in-person exam with another provider. SSRIs and other non-controlled anxiety medications would be unaffected. Many platforms are preparing hybrid models for this scenario. The mental health community is actively advocating for permanent telehealth flexibility given the access-to-care crisis.

Final Word: Regulation as Infrastructure, Not Barrier

If you got into psychiatry or psychiatric nursing to treat anxiety disorders, regulations probably weren’t the appeal. But here’s the reality: understanding this landscape is infrastructure for your practice, not a barrier to it.

The providers who thrive in telehealth understand their scope, know which states offer the best practice environment for their license type, stay current on federal rules, and partner with platforms that handle the administrative heavy lifting.

Anxiety disorders affect 40 million adults in the U.S. The demand for qualified prescribers far exceeds supply. Telehealth has proven it can deliver effective, safe anxiety treatment at scale — and the regulatory environment, despite its complexity, is moving toward supporting that.

Whether you’re an established psychiatrist looking to expand via telehealth, a newly minted PMHNP choosing where to get licensed, or an experienced NP considering full practice authority states — the opportunities are significant. The regulations are manageable with the right knowledge and infrastructure.

Platforms like Klarity Health exist precisely because navigating this patchwork solo is inefficient. We handle multi-state compliance, provide collaborating physicians where needed, integrate PDMP systems and e-prescribing, and deliver qualified patients ready for treatment. You focus on what you do best: evaluating and treating anxiety disorders.

The regulatory landscape will keep evolving — that’s guaranteed. But providers who understand the rules, stay adaptable, and align with the right partners will continue building thriving practices while delivering care that changes lives.

Ready to explore telehealth practice with full compliance support and a steady flow of anxiety patients? Learn more about joining Klarity Health’s provider network.

References and Sources

1. U.S. Drug Enforcement Administration (DEA). ‘DEA and HHS Extend Telemedicine Flexibilities Through 2025.’ November 15, 2024. Official DEA announcement on telehealth prescribing extension. https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. Center for Connected Health Policy (CCHP). ‘State Telehealth Policies: Online Prescribing.’ Updated January 9, 2026. Comprehensive state-by-state analysis of telehealth prescribing laws with official citations. https://www.cchpca.org/topic/online-prescribing/

3. Florida Legislature. Florida Statutes §456.47 (Telehealth Services) and §464.012 (Advanced Practice Registered Nurses). 2025 edition. Official state statutes governing telehealth practice and APRN prescribing including controlled substance limitations. http://www.leg.state.fl.us/Statutes/

4. Texas Board of Nursing. ‘APRN Prescriptive Authority FAQ.’ Updated December 9, 2025. Official guidance on Schedule II prescribing restrictions for APRNs in Texas. https://www.bon.texas.gov/faqpracticeaprn.asp.html

5. New York State Department of Health. ‘Prescription Monitoring Program (I-STOP).’ Effective August 27, 2013 (ongoing). Requirements for mandatory PDMP consultation for Schedule II-IV prescriptions. https://health.ny.gov/professionals/narcotic/prescription_monitoring

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94